跳到正文
BioPharm International·· 11 天前AI 评分19

cGMP合规药品包装企业评估:产品完整性与全球供应所需能力

cGMP-Compliant Pharmaceutical Packaging Companies: Capabilities to Evaluate for Product Integrity and Global Supply

AI 导读

选择cGMP合规的药品包装企业需审查其合规体系与防护设计,全球采购覆盖、安全特性和对患者结局的影响与价格和速度同等重要。单次受损运输即可抵消多年制剂工作,引发监管扣留或危及全球供应链中的患者安全。

正文 · 原文

News|Articles|November 11, 2026

A single compromised shipment can undo years of formulation work, trigger a regulatory hold or put patient safety at risk across the global supply chain. Selecting a current Good Manufacturing Practice (cGMP) compliant pharmaceutical packaging company means scrutinizing its compliance systems and protective design. Global sourcing reach, security features and impact on patient outcomes matter just as much as price and speed.

Related to this article

The BioPharm Brief: Base Editing Hits Its Mark in Sickle Cell, a Phase 3 Win in Sjögren’s, and Off-the-Shelf CAR-T in Lupus

November 11th, 2026

Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.

Read more

Q&A: Who Is Accountable When AI Gets Drug Development Wrong?

November 11th, 2026

Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.

Read more

ProBio licenses a discovery-stage oncology antibody to AbTis, which plans to develop it as a bispecific, site-specific antibody-drug conjugate. Credit: Stock.Adobe.com/AddMeshCube

November 11th, 2026

ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.

Read more

3D illustration of a translucent blue human torso, viewed from the front, with both kidneys highlighted in pink and the rib cage, liver, and intestines faintly visible. | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 11th, 2026

ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.

Read more

Beam plans to file the first U.S. application for a base-editing therapy after BEACON met its primary endpoint in sickle cell disease. Credit: Stock.Adobe.com/freshidea

November 11th, 2026

Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.

Read more

Close-up photograph of a person using their fingers to hold open a reddened eye while squeezing a drop from a small white-and-blue dropper bottle into it. | Image Credit: © TatjanaMeininger - stock.adobe.com

November 11th, 2026

Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.

Read more

After a three-year research collaboration, AstraZeneca has acquired Omniose, whose platform builds conjugate vaccine components inside one E. coli cell. Credit: Stock.Adobe.com/Valeriya Zankovych

November 10th, 2026

AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.

Read more

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide

November 10th, 2026

FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.

Read more

来源:BioPharm International · biopharminternational.com